The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index; 7 of the 30 sources its claims cite were checked for support.
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
Open accessAbstract
BACKGROUND: mRNA with volanesorsen led to decreased plasma apolipoprotein C-III and triglyceride levels. METHODS: We conducted a phase 3, double-blind, randomized 52-week trial to evaluate the safety and effectiveness of volanesorsen in 66 patients with familial chylomicronemia syndrome. Patients were randomly assigned, in a 1:1 ratio, to receive volanesorsen or placebo. The primary end point was the percentage change in fasting triglyceride levels from baseline to 3 months. RESULTS: Patients receiving volanesorsen had a decrease in mean plasma apolipoprotein C-III levels from baseline of 25.7 mg per deciliter, corresponding to an 84% decrease at 3 months, whereas patients receiving placebo had an increase in mean plasma apolipoprotein C-III levels from baseline of 1.9 mg per deciliter, corresponding to a 6.1% increase (P<0.001). Patients receiving volanesorsen had a 77% decrease in mean triglyceride levels, corresponding to a mean decrease of 1712 mg per deciliter (19.3 mmol per liter) (95% confidence interval [CI], 1330 to 2094 mg per deciliter [15.0 to 23.6 mmol per liter]), whereas patients receiving placebo had an 18% increase in mean triglyceride levels, corresponding to an increase of 92.0 mg per deciliter (1.0 mmol per liter) (95% CI, -301.0 to 486 mg per deciliter [-3.4 to 5.5 mmol per liter]) (P<0.001). At 3 months, 77% of the patients in the volanesorsen group, as compared with 10% of patients in the placebo group, had triglyceride levels of less than 750 mg per deciliter (8.5 mmol per liter). A total of 20 of 33 patients who received volanesorsen had injection-site reactions, whereas none of the patients who received placebo had such reactions. No patients in the placebo group had platelet counts below 100,000 per microliter, whereas 15 of 33 patients in the volanesorsen group had such levels, including 2 who had levels below 25,000 per microliter. No patient had platelet counts below 50,000 per microliter after enhanced platelet-monitoring began. CONCLUSIONS: Volanesorsen lowered triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome. Thrombocytopenia and injection-site reactions were common adverse events. (Funded by Ionis Pharmaceuticals and Akcea Therapeutics; APPROACH Clinical Trials.gov number, NCT02211209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 15 Not checked · 60 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These data show that volanesorsenmediated lowering of apolipoprotein C-III effectively enhances clearance of triglyceride-rich lipoproteins in patients without LPL activity.27”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Partly supportedcites [27] sourceExperimental — accuracy not yet measured
The Introduction (p. n/a) states that volanesorsen 'dramatically lowered elevated plasma TG levels in patients who have genetic defects in LPL (familial chylomicronemia syndrome [FCS])' and that, despite the absence of a placebo control group, 'this finding suggests that ApoC-III impairs TG clearance predominantly in an LPL-independent fashion'; the Discussion adds that their mouse data are 'consistent with the recent observation that targeting of ApoC-III effectively reduces plasma TGs in LPL-deficient patients'. So the enhanced-clearance-in-LPL-deficient-patients reading is present, but the source hedges it as a suggestion inferred from TG lowering (clearance itself was measured only in mice) and explicitly flags the uncontrolled design; the Discussion also notes the FCS subjects had a mutated LPL with possible residual activity rather than a strict absence. The citing sentence's unhedged 'these data show ... effectively enhances clearance' therefore overstates what this source attributes to the trial. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
None of the sources cited for this claim have been checked yet.
In the paper
“The APPROACH trial showed that volanesorsenmediated lowering of plasma apolipoprotein C-III levels in patients with familial chylomicronemia syndrome effectively lowered plasma triglycerides below the threshold of 750 to 880 mg per deciliter”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Discussion
What the sources say
- Not checked yetcites [6] source
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Our copy of the NLA Part 2 recommendations contains no mention of volanesorsen, apolipoprotein C-III as a therapeutic target, or the APPROACH trial (searched: 'volanesorsen APPROACH trial apolipoprotein C-III familial chylomicronemia syndrome', 'apolipoprotein C-III antisense oligonucleotide new therapies', 'severe hypertriglyceridemia pancreatitis threshold'). The closest passages cover only established therapy for very high TG — the 'Dietary considerations for management of hypertriglyceridemia' and 'Targets of lifestyle therapies' sections set the pancreatitis-prevention goal at lowering TG to <500 mg/dL (noting chylomicronemia is often present at ≥750 mg/dL), and the 'Non-statin recommendations' / 'Fibrates' sections discuss fenofibrate and prescription omega-3s — so nothing here speaks to the trial result attributed to this source. Our copy is also flagged as truncated, so the decisive text may be missing. (LLM, conf=0.72)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
Our copy of the 2012 Endocrine Society guideline contains no mention of volanesorsen, the APPROACH trial, or an antisense apoC-III oligonucleotide (searched: 'volanesorsen APPROACH trial apolipoprotein C-III antisense', 'antisense oligonucleotide apoC-III inhibitor', '750 mg/dl triglyceride threshold'); apoC-III appears only in pathophysiology/kinetics references. Nor does it give a 750-880 mg/dl pancreatitis threshold: the Chylomicronemia syndrome section states pancreatitis risk 'markedly increases with very severe triglyceride levels above 2000 mg/dl' and 'can be prevented by maintaining triglyceride levels below 1000 mg/dl', and the Fibrates section sets a treatment goal of <1000 mg/dl. The trial result attributed here is therefore not addressed by this source at all (the guideline predates the APPROACH trial), so the claim cannot be checked against it. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“findings that support the hypothesis that apolipoprotein C-III also inhibits an LPL-independent pathway of triglyceride-rich lipoprotein clearance.16”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > F
What the sources say
- Supportedcites [16] source
The Discussion says the study's findings suggest that APOC3 regulates triglyceride-rich lipoprotein metabolism through LPL-independent pathways. The Figure 2 caption states more specifically that APOC3 has an inhibitory role in that pathway, matching the citing sentence's hypothesis. (LLM, conf=0.94)
hedgedstates a causen = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three other patients with lesser grades (grade 1 or 2) of decreased platelet counts were withdrawn from the trial because of concerns on the part of the site investigators.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourteen patients assigned to volanesorsen, as compared with 2 patients assigned to placebo, did not complete the 52-week trial”
- Also stated in: § 541 · plain
“Fourteen patients in the volanesorsen group discontinued the trial: 9 because of adverse events that occurred during treatment (including 5 who had decreases in platelet counts and 4 because of other drug-related side effects), and 5 primarily because of issues related to requirements of the protocol.”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 541 · plain
22 more claims
Create a free account to see all 79 claims and to verify the 23 references still open.
- Probably not a substantial claim. 21
- It may state two separate claims as one. 38
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Our findings are consistent with the observations that LDL cholesterol levels are typically very low (<20 mg per deciliter [0.52 mmol per liter]) and total apolipoprotein B levels are within the low-to-normal range in persons with familial chylomicronemia syndrome. 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a previous trial involving patients with familial chylomicronemia syndrome, the administration of volanesorsen at a weekly dose of 300 mg per deciliter over a 3-month period was accompanied by reductions in apolipoprotein C-III and triglyceride levels of 84% and 77%, respectively, 25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While APPROACH was not powered to detect clinical endpoints, exploratory analyses showed a meaningful reduction in pancreatitis episodes among patients who achieved sustained TG levels below 500 mg/dL— considered by some to be a threshold for pancreatitis risk [44].”
From Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“its safety profile, particularly the high incidence of thrombocytopenia, has limited broader clinical adoption [115]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [115]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Reduced platelet counts below 100 000 per microliter was a common adverse event in the volanesorsen group (15 of 33 patients, two patients with levels < 25 000 per microliter).74”
From Clinical review on triglycerides (2020) · cites this paper as [74]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Abstract
“15 of 33 patients in the volanesorsen group had such levels”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Safety
“confirmed nadir levels below 100,000 per microliter were observed in 16 patients (48%) who received volanesorsen”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“1933 mg per deciliter [22.5 mmol per liter]”
§ Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome > Secondary Efficacy End Points
Reported 22.5 · recomputed 21.82357
Citations
Cites
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationIssues in Hypertriglyceridemic Pancreatitis: An Update
Scherer, J., Singh, V. P., Pitchumoni, C. S., & Yadav, D. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000436438.60145.5a · Cited by 475
Current knowledge of hypertriglyceridemic pancreatitis
Valdivielso, P., Ramírez-Bueno, A., & Ewald, N. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2014.08.008 · Cited by 439
Chylomicronaemia–current diagnosis and future therapies
Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
Research works printed but not linked: 1
- Brunzell JD Deeb SS. Familial lipoprotein lipase deficiency apo CII deficiency and hepatic lipase deficiency. In: Scriver CR Beaudet AL Sly WS et al. eds. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill 2000:2789-816.
Cited by
Items 201–300 of 673
New and Emerging lipid-lowering Therapy
Backes, J. M., & Hilleman, D. E. (2021) · Future Cardiology · doi:10.2217/fca-2020-0217 · Cited by 21
Present and Future of Dyslipidaemia Treatment—A Review
Merćep, I., Vujević, A., Strikić, D., Radman, I. B., Pećin, I., & Reiner, Ž. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185839 · Cited by 25
RNA nanomedicine in liver diseases
Bakrania, A. K., Mo, Y., Zheng, G., & Bhat, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000606 · Cited by 25
“Also, a 77% decrease in triglyceride levels was observed in patients treated with volanesorsen as opposed to an 18% increase in patients treated with a placebo [65] a For patients weighing ≥ 20 kg.”
Reza, N., Alford, R. L., Belmont, J. W., & Marston, N. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02003-4 · Cited by 23
Bashir, B., Kwok, S., Wierzbicki, A. S., Jones, A. F., Dawson, C., Downie, P., Jenkinson, F., Delaney, H., Mansfield, M. W., Datta, D. B. N., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117476 · Cited by 23
Self-citationLipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Shang, R., & Rodrigues, B. B. (2024) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2024.13199 · Cited by 21
“Related to targeting APOC3, two antisense oligonucleotides, Olezarsen and Volanesorsen, are currently in Phase 3 clinical trials to determine their therapeutic potential to lower circulating TG [129, 130].”
BackgroundGene therapy for polygenic or complex diseases
Wu, T., Hu, Y., & Tang, L. V. (2024) · Biomarker Research · doi:10.1186/s40364-024-00618-5 · Cited by 27
A novel GPIHBP1 mutation related to familial chylomicronemia syndrome: A series of cases
Lima, J. G., Nóbrega, L. H. C., Bandeira, F. T. M., de Sousa, A. G. P., Macedo, T. B. M. D. A., Nogueira, A. C. C., Filho, A. F. D. O., Alves, R. J., Castelo, M. H. C. G., Coelho, F. M. S., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.020 · Cited by 22
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 25
Familial chylomicronemia syndrome and treatments to target hepatic APOC3 mRNA
Brinton, E. A., Eckel, R. H., Gaudet, D., Ballantyne, C. M., Baker, B. F., Ginsberg, H. N., & Witztum, J. L. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119114 · Cited by 22
Self-citationTrafficking of Mononuclear Phagocytes in Healthy Arteries and Atherosclerosis
Tomas, L., Prica, F., & Schulz, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718432 · Cited by 23
Poller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 22
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
Qiao, Y., Wotring, J. W., Zhang, C. J., Jiang, X., Xiao, L., Watt, A., Gattis, D., Scandalis, E., Freier, S. M., Zheng, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281281 · Cited by 21
“Antisense oligonucleotides (ASOs) are a rapidly expanding class of therapeutics with clinical efficacy in multiple diseases [15, 16], including several that have received approval by the Food and Drug Administration (FDA): nusinersen for spinal muscular atrophy [17, 18]; eteplirsen [19], golodirsen [20], and viltolars…”
BackgroundIs Genetic Testing in Hypertriglyceridemia Useful?
Hegele, R. A. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.318621 · Cited by 20
Pan, B.-Y., Chen, C.-S., Chen, F.-Y., & Shen, M.-Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312759 · Cited by 19
Patel, S. B., Belalcazar, L. M., Afreen, S., Balderas, R., Hegele, R. A., Karpe, F., Ponte-Negretti, C. I., & Rajpal, A. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.014 · Cited by 23
Karwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
“…apoC-III has become a target of therapy for patients with familial chylomicronemia syndrome (FCS), with several studies leading to the approval of vol-anesorsen (Waylivra ® ) in the European Union for this indication[3, 5–7] and in Brazil for both FCS and familial partial lipodystrophy [8].”
BackgroundSelf-citationNovel Experimental Agents for the Treatment of Hypercholesterolemia
Pećin, I., & Reiner, Ž. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s267376 · Cited by 21
Decoding the interactions and functions of non-coding RNA with artificial intelligence
Jung, V., Vincent-Cuaz, C., Tumescheit, C., Fournier, L. M., Darsinou, M., Xu, Z. M., Saadat, A., Wang, Y., Tsantoulis, P. K., Michielin, O. A., et al. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00857-w · Cited by 19
Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve, V., Millán, J., Blanco, A., Blasco, M., Díaz-Díaz, J. L., Rodríguez, Á. D., Mangas, A., Pascual, V., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.02.001 · Cited by 28
Shen, X., Wong, J., Prakash, T. P., Rigo, F., Li, Y., Напиерала, М., & Corey, D. R. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115472 · Cited by 20
Soto, L. G. D. L. P., Gutierrez-Uribe, J. A., Sharma, A. K., & Ramírez‐Jiménez, A. K. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.035 · Cited by 19
Transcriptomic Therapy for Dyslipidemias Utilizing Nucleic Acids Targeted at ANGPTL3
Watts, G. F., Raal, F. J., & Chan, D. C. (2021) · Future Cardiology · doi:10.2217/fca-2021-0096 · Cited by 18
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Ward, N. C., Chan, D. C., & Watts, G. F. (2022) · BioDrugs · doi:10.1007/s40259-022-00520-2 · Cited by 20
“A significant portion of the volanesorsen group experienced injection-site reactions, which were not observed in the placebo group, and 45% of the volanesorsen group also experienced severe thrombocytopenia [79].”
BackgroundMethodRecent Updates in Hypertriglyceridemia Management for Cardiovascular Disease Prevention
Quispe, R., Sweeney, T. E., Varma, B., Agarwala, A., & Michos, E. D. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01052-4 · Cited by 18
Hussain, A., & Ballantyne, C. M. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-100119-013612 · Cited by 22
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
“Four of these studies investigated the effects of volanesorsen [18, 25, 26, 38], three examined the impact of Plozasiran [19, 37, 40], and the remaining three studied olezarsen [20, 39–41].”
InfluentialRenal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
“The phase III trials showed that treatment with volanesorsen leads to a robust decrease in both apoC-III production and triglyceride concentrations up to 70% even in the more severe genetic form of hypertriglyceridemia such as FCS [145].”
Self-citationLiu, Y., Wang, H. H., Yu, M., Cai, L., Zhao, Y., Cheng, Y., Deng, Y., Zhao, Y., Lu, H., Wu, X., et al. (2025) · Circulation · doi:10.1161/circulationaha.125.074737 · Cited by 21
Introduction and History of the Chemistry of Nucleic Acids Therapeutics
Gait, M. J., & Agrawal, S. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2010-6_1 · Cited by 21
“These include inotersen [106], volanesorsen [107], and mipomersen [108].”
BackgroundEtiology and emerging treatments for familial chylomicronemia syndrome
Spagnuolo, C. M., & Hegele, R. A. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365787 · Cited by 20
“These reductions in plasma levels of TG and apo C-III were similar to those observed in the APPROACH trial of volanesorsen in patients with FCS [18].”
BackgroundResultInfluentialAn overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Self-citationAnti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease
Tsimikas, S. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01345-4 · Cited by 16
“The Phase 3 APPROACH trial evaluated the efficacy and safety of subcutaneous volanesorsen (300 mg once weekly) in 66 patients with FCS over 52 weeks [36 ].”
Self-citationNon-coding RNAs in the pathophysiology of heart failure with preserved ejection fraction
Jalink, E. A., Schonk, A. W., Boon, R. A., & Juni, R. P. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1300375 · Cited by 18
Silbernagel, G., Scharnagl, H., Kleber, M. E., Hoffmann, M. M., Delgado, G., Stojaković, T., Gary, T., Zeng, L., Ritsch, A., Zewinger, S., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.017 · Cited by 17
Pharmacokinetics of current and emerging treatments for hypercholesterolemia
Tomlinson, B., Chan, P., Zhang, Y., Liu, Z., & Lam, C. W. K. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749261 · Cited by 17
“It has been associated with thrombocytopenia although the mechanism is not known [136].”
BackgroundAPOC3 Interference for Familial Chylomicronaemia Syndrome
Hegele, R. A. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.82 · Cited by 17
“In APPROACH, 66 patients were studied, 52 of whom had genetically diagnosed FCS: 33 received volanesorsen 300 mg subcutaneously once weekly, and 33 received matching doses of placebo.(7,9) At 3 months, volanesorsen was associated with placebo-adjusted reductions of around 90% in apo C-III and TG levels, with beneficia…”
BackgroundMethodInfluentialNovel RNA-Based Therapies in the Management of Dyslipidemias
Kosmas, C. E., Bousvarou, M. D., Tsamoulis, D., Gianniou, M., Papakonstantinou, E. J., & Rallidis, L. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031026 · Cited by 19
“Two patients had platelet counts below 25,000/ µ L. Injection-site reactions occurred in 60.6% of the patients in the volanesorsen group, compared to none in the placebo group [38].”
InfluentialJoint Associations of APOC3 and LDL-C–Lowering Variants With the Risk of Coronary Heart Disease
Wang, W., Li, R. P., Song, Z., Huang, N., Huang, T., Hua, X., & Tang, Y.-D. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0195 · Cited by 16
Sun, Y., Nitta, S.-I., Saito, K., Hosogai, R., Nakai, K., Goda, R., Kakehi, M., Murata, K., Yamaguchi, T., Okuzono, T., et al. (2020) · Bioanalysis · doi:10.4155/bio-2020-0225 · Cited by 15
Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia
Hooper, A. J., Bell, D. A., & Burnett, J. R. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2408369 · Cited by 17
“TG reductions of ~ 60% at 6 months from baseline were observed APOC3 ASO FCS –77% (III) [26] Approved in the EU, UK and Brazil for FCS. Reduced incidence of acute pancreatitis (OR 0.18) [27].”
Influentialde Souza, M. D. M., Mendes, B. X., Defante, M. L. R., Morais, B. A. D. A. D. H., Martins, O. C., Prizão, V. M., & Romaniello, G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156187 · Cited by 16
Bergmark, B. A., Marston, N., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Murphy, S. A., Zhang, S. M., Lu, M. T., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.022 · Cited by 17
Self-citationThe triglyceride to HDL-cholesterol ratio and chronic graft failure in renal transplantation
Anderson, J. L. C., Bakker, S. J. L., & Tietge, U. J. F. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.01.009 · Cited by 18
Shaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
The impact of lipid-lowering medications on coronary artery plaque characteristics
Pulipati, V. P., & Alenghat, F. J. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100294 · Cited by 17
How to Handle Elevated Triglycerides: Life after PROMINENT
Pirillo, A., & Catapano, A. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01175-2 · Cited by 16
“Volanesorsen significantly reduced levels of TG and the risk of recurrent pancreatitis in FCS patients [25].”
InfluentialXiao, Q., Wang, J., Wang, L., & Ding, H. (2024) · Biomedicines · doi:10.3390/biomedicines12061224 · Cited by 14
“Consequently, it has received approval for treating FCS [74,75].”
BackgroundThe Role of Antisense Therapies Targeting Lipoprotein(a)
Plakogiannis, R., Sorbera, M. A., Fischetti, B., & Chen, M. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001045 · Cited by 14
Recent Apolipoprotein CIII trials
Tramontano, D., Bini, S., D’Erasmo, L., & Arca, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000849 · Cited by 14
Self-citationFlorentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
“The respective changes at 6 and 12 months were −53% vs +25% and −40% vs +9% [46].”
BackgroundMethodInfluentialProprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 15
“In trials using the single-stranded antisense oligonucleotides (ASO), patients have developed thrombocytopenia [17].”
BackgroundHypertriglyceridemia: molecular and genetic landscapes
Scicchitano, P., Amati, F., Ciccone, M. M., D’Ascenzi, F., Imbalzano, E., Liga, R., Paolillo, S., Pastore, M. C., Rinaldi, A., Mattioli, A. V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126364 · Cited by 13
Ren, Z., Zhou, J., Yang, D., Guo, Y., Zhang, J., Xu, J., & Chen, Y. E. (2026) · Cells · doi:10.3390/cells15020134 · Cited by 15
“…carrying loss-of-function mutations in ApoC3 exhibit lower plasma triglyceride levels and a substantially reduced risk of coronary heart disease [157], and even heterozygous carriers tend to have reduced triglyceride compared to non-carriers [158]. https://doi.org/10.3390/cells15020134 5.4.”
InfluentialMatza, L. S., Phillips, G. A., Howell, T. A., Ciffone, N. A., & Ahmad, Z. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1776719 · Cited by 13
Recent progress in gene therapy for familial hypercholesterolemia treatment
Luo, Y., Hou, Y., Zhao, W., & Yang, B. (2024) · iScience · doi:10.1016/j.isci.2024.110641 · Cited by 15
“87 However, thrombocytopenia was observed in about half of the participants, therefore volanesorsen is approved with restrictions in Europe but not in the US.”
BackgroundMarston, N. A., Bergmark, B. A., Alexander, V. J., Karwatowska‐Prokopczuk, E., Kang, Y. M., Moura, F. A., Prohaska, T. A., Zimerman, A., Zhang, S. M., Murphy, S. A., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.03.003 · Cited by 13
Self-citationNovel Therapeutics for Familial Chylomicronemia Syndrome
Izar, M. C. D. O., & Fonseca, F. A. H. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01295-x · Cited by 13
“Importantly, the trial observed a significant decrease in acute pancreatitis (AP) events, from 82 pre-treatment cases to just 4 during treatment, though a placebo-controlled comparison was unavailable [36].”
Mszar, R., Bart, S., Sakers, A. P., Soffer, D. E., & Karalis, D. G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041382 · Cited by 16
“Several years later, in a phase 3, double-blinded RCT of patients with FCS (N = 66), volanesorsen lowered TG levels to <750 mg/dL in 77% of participants; however, a large proportion of patients in the volanesorsen group reported thrombocytopenia and injection-site reactions [77].”
BackgroundNovel therapeutic targets and agents for pediatric dyslipidemia
Sunil, B., Foster, C., Wilson, D. P., & Ashraf, A. P. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211058323 · Cited by 14
Masson, W., Lobo, M., Nogueira, J. P., Corral, P., Barbagelata, L., & Siniawski, D. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09893-x · Cited by 12
“Additionally, one study enrolled patients with severe hypertriglyceridemia, some of whom were diagnosed with FCS [12], while another two studies exclusively recruited patients with this condition [11, 17].”
Prevention and treatment of hypertriglyceridemia-mediated acute pancreatitis: A narrative review
Subramanian, S., Soran, H., Kessler, A. S., McClain, M. R., Eckel, R. H., & Rosenson, R. S. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106648 · Cited by 13
Self-citationAtherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease
Girón, G. O., Otero, S., Nikolaou, P., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pagés, M., Padró, T., Suades, R., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70167 · Cited by 13
“183,184 Olezarsen and plozasiran, more targeted RNA-based therapies, showed similar TG-lowering efficacy and fewer side effects, such as thrombocytopenia.”
Reyes‐Soffer, G. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000619 · Cited by 13
Ferro, F., Spelat, R., Pandit, A. S., Martín-Ventura, J. L., Rabinovich, G. A., & Contessotto, P. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.013 · Cited by 14
Tsimikas, S., Ginsberg, H. N., Alexander, V. J., Karwatowska‐Prokopczuk, E., Dibble, A., Li, L., Witztum, J. L., & Hegele, R. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.018 · Cited by 12
Self-citationA guide to RNA structure analysis and RNA ‐targeting methods
Aguilar, R., Mardones, C., Moreno, A. A., & Cepeda‐Plaza, M. (2024) · FEBS Journal · doi:10.1111/febs.17368 · Cited by 17
Remnant cholesterol, vascular risk, and prevention of atherosclerosis
Pintó, X., Fanlo‐Maresma, M., Esteve-Luque, V., & Millán, J. (2023) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2023.07.005 · Cited by 18
The brave new world of genetic testing in the management of the dyslipidaemias
Nawawi, H. M., Chua, Y.-A., & Watts, G. F. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000721 · Cited by 12
“Common gene mutations that cause familial chylomicronaemia are lipoprotein lipase (LPL), apolipoprotein C2 (APOC2), apolipoprotein A-V (APOA5), lipase maturation factor 1 (LMF1) and Glycosylphosphatidylinositol anchored high-density lipoprotein binding protein 1 (GPIHBP1) genes [3 && ].”
BackgroundIitake, C., Masuda, D., Koseki, M., & Yamashita, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01172-8 · Cited by 14
Approach to the Patient With Moderate Hypertriglyceridemia
Subramanian, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac085 · Cited by 13
Personalized Medicine in Lipid-Modifying Therapy
Tomlinson, B., Lin, C.-H., Chan, P., & Lam, C. W. K. (2021) · Personalized Medicine · doi:10.2217/pme-2020-0110 · Cited by 12
Maidman, S. D., Hegele, R. A., & Rosenson, R. S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01258-8 · Cited by 14
“In APPROACH, 66 patients with FCS and very severe hypertriglyceridemia (fasting TG > 750 mg/dL or > 8.5 mmol/L) were randomized to receive 300 mg subcutaneously once a week for 52 weeks [8].”
InfluentialGarcia, D. A., Powers, A. F., Bell, T. A., Guo, S., & Aghajan, M. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0029 · Cited by 13
Advances in the care of lipodystrophies
Shamsudeen, I., & Hegele, R. A. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000695 · Cited by 11
“Adverse events included thrombocytopenia with platelets <100 000/ml (15/ 33 patients); two patients had platelets <25 000/ml [52], an adverse effect that may ultimately limit access to this medication.”
BackgroundMethodInfluentialDo Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
“Consequently, it is possible that therapies more specifically lowering TRLs, such as fibrates and apolipoprotein C3 inhibitors, may have a more important role in treatment and prevention of acute pancreatitis and/or nonalcoholic fatty liver disease caused by elevated triglycerides [55, 56 • ].”
BackgroundGuay, S., Paquette, M., Taschereau, A., Desgagné, V., Bouchard, L., Bernard, S., & Baass, A. W. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.02.007 · Cited by 12
Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications
Zubirán, R., Cruz‐Bautista, I., & Aguilar-Salinas, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01626-2 · Cited by 13
“[102].”
BackgroundJin, L., Hong, N., Ai, X., Wang, J., Li, Z., Han, Z., Zhang, Q., Yu, Y., & Sun, K. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200320161835 · Cited by 12
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
Parhofer, K. G., Chapman, M. J., & Nordestgaard, B. G. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa116 · Cited by 12
“Volanesorsen Volanesorsen is a second-generation chimeric antisense inhibitor, which impairs the translation of apolipoprotein CIII mRNA.(56,57) It is approved in Europe for the treatment of patients with genetically proven familial chylomicronemia syndrome and therefore with elevated risk for pancreatitis.”
BackgroundLightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
“However, a causal role for reduced apoC-III leading to triglyceride lowering is more strongly supported by recent clinical trials of an antisense oligonucleotide to lower apoC-III in patients with familial chylomicronemia syndrome [40, 43, 44].”
BackgroundFamilial chylomicronemia syndrome in children: a diagnosis challenge
Ariza, M. J., & Valdivielso, P. (2022) · Translational Pediatrics · doi:10.21037/tp-22-515 · Cited by 13
Chronic and Idiopathic Pancreatitis—A Personalized Treatment Approach
von Widdern, J. C., Rosendahl, J., & Ammer‐Herrmenau, C. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12741 · Cited by 11
“Two antisense oligonucleotide drugs, Olezarsen and Vola-nesoren, have proven efficiency in placebo controlled trials, decreasing both triglyceride plasma levels and the rate of pancreatitis episodes [27, 28].”
Research advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
“A 52‑week phase III trial of Volanesorsen in 66 patients with FCS (APPROACH; NCT no. 02211209) (221), after treatment, mean TG levels decreased by 77%.”
The Era of Gene Therapy: The Advancement of Lentiviral Vectors and Their Pseudotyping
Jargalsaikhan, B.-E., Muto, M., & Ema, M. (2025) · Viruses · doi:10.3390/v17081036 · Cited by 14
A practical guide to the management of dyslipidaemia
Siegel, P. M., Katzmann, J. L., Weinmann‐Menke, J., Landmesser, U., Schunkert, H., Baldus, S. E., Böhm, M., Laufs, U., Lüscher, T. F., & Hilgendorf, I. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02833-y · Cited by 14
“These patients require close surveillance because of thrombocytopenia as an adverse effect, among others [61].”
Iannuzzi, A., Annunziata, M., Fortunato, G., Giacobbe, C., Palma, D., Bresciani, A., Aliberti, E., & Iannuzzo, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.832890 · Cited by 10
“Elevated plasma levels of APOC3 are also considered as a major risk factor for hypertriglyceridemia (Witztum et al., 2019).”
BackgroundCheng, Y., Li, T., Tan, P., Du, Y., Huang, Z., Shi, H., Cai, T., Chen, Y., & Fu, W. (2022) · Endocrine · doi:10.1007/s12020-022-03025-8 · Cited by 11
RNA interference-based therapies for the control of atherosclerosis risk factors
Kettunen, S., Ruotsalainen, A., & Ylä‐Herttuala, S. (2022) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000972 · Cited by 12
“Reduction of ANGPTL3 levels has been associated with lower plasma TGs and cholesterol levels in humans, both naturally with genetic loss-of-function mutations [29] and therapeutically [26,30,31].”
BackgroundA New Modality in Dyslipidemia Treatment: Antisense Oligonucleotide Therapy
Kim, K., & Choi, S. H. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.3.250 · Cited by 11
Effects of combinations of gapmer antisense oligonucleotides on the target reduction
Yanagidaira, M., Yoshioka, K., Nagata, T., Nakao, S., Miyata, K., & Yokota, T. (2023) · Molecular Biology Reports · doi:10.1007/s11033-022-08224-0 · Cited by 10
“Gapmers, which can downregulate disease-related gene expression, have been approved for clinical use [6, 7].”
BackgroundJacobsen, A. P., Whelton, S. P., Blumenthal, R. S., & McEvoy, J. W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00042-6 · Cited by 22
A Novel APOC2 Mutation in a Colombian Patient with Recurrent Hypertriglyceridemic Pancreatitis
Pinilla-Monsalve, G. D., Lores, J., Pachajoa, H., de León, J. D. L., López, A., Rodríguez‐Rojas, L. X., & Nastasi-Catanese, J. A. (2020) · The Application of Clinical Genetics · doi:10.2147/tacg.s243148 · Cited by 10
“The main adverse effects included injection-site reactions, thrombocytopenia, and abdominal pain, an event that seems paradoxical in the context of the disease clinical manifestations.(26) Our patient might not benefit from this therapy taking into account the lack of solid evidence for treating HTG caused by APOC2 mu…”
BackgroundBiotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“The APPROACH (NCT02211209) [143] and COMPASS (NCT02300233) [144] phase 3 studies evaluated the longterm efficacy and safety of volanesorsen (at the dose of 300 mg SC QW) in patients with familial chylomicronemia syndrome and hypertriglyceridemia, respectively.”
BackgroundRole of Genetics in Preventive Cardiology: Focused on Dyslipidemia
Lee, S. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0239 · Cited by 10
Insights from ORION studies: focus on inclisiran safety
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa139 · Cited by 10
Olezarsen for the Treatment of Familial Chylomicronemia Syndrome
Phillips, B., Abbott, C., Breit, S., & Onge, E. S. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251332500 · Cited by 10
“22,23 Olezarsen is the first FDA-approved antisense oligonucleotide for FCS in adult patients as an adjunct to dietary measures.”
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?
Biolo, M., Galimberti, F., Portinari, C., Bertocco, S., Tosin, P., Casula, M., Previato, L., Zambon, S., Simioni, P., & Zambon, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01315-w · Cited by 9
“These findings were confirmed in the Phase 3 APPROACH trial—a randomized, double-blind, 52-week study including 66 FCS patients [14].”
D’Erasmo, L., Tramontano, D., Di Costanzo, A., Casula, M., Galimberti, F., Baratta, F., Cefalù, A. B., Tarugi, P. M., Calandra, S., Zambon, A., et al. (2025) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.125.323340 · Cited by 9
Self-citation
Metadata
- Authors
- Witztum, J. L., Gaudet, D., Freedman, S. D., Alexander, V. J., Digenio, A., Williams, K. R., Yang, Q., Hughes, S. G., Geary, R. S., Arca, M., Stroes, E. S. G., Bergeron, J., Soran, H., Civeira, F., Hemphill, L., Tsimikas, S., Blom, D. J., O’Dea, L., & Bruckert, E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- From the Department of Medicine, University of California San Diego, La Jolla (J.L.W., S.T.), and Ionis Pharmaceuticals, Carlsbad (V.J.A., Q.Y., S.G.H., R.S.G., S.T.) — both in California; the Department of Medicine, Université de Montréal and ECOGENE 21, Chicoutimi, QC (D.G.), and the Department of Medicine and Laboratory Medicine, Centre Hospitalier Universitaire de Québec–University Laval, Quebec, QC (J.B.) — both in Canada; the Department of Medicine, Beth Israel Deaconess Medical Center (S.D.F....
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-08
- Volume
- 381
- Issue
- 6
- Pages
- 531-542
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2966503756
- Semantic Scholar
- 1b419fba1e6af00f305b1f8b0ee92c239fec7d40
- Cited by
- 669
- References
- 34
- Citations by year
- 2026: 88 · 2025: 112 · 2024: 112 · 2023: 77 · 2022: 95 · 2021: 91 · 2020: 79 · 2019: 14
- FWCI
- 50.23
- Type
- journal article
- Language
- en
- Open access
- green
- pure.amsterdamumc.nl
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Zaguan (University of Zaragoza Repository) (submittedVersion)
- Funders
- Akcea Therapeutics
- Ionis Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- volanesorsen, familial chylomicronemia syndrome, apolipoprotein C-III, triglyceride levels, antisense therapy, hypertriglyceridemia, injection site reactions, platelet count, treatment efficacy and safety, triglyceride lowering
- MeSH terms
- Adult, Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Hyperlipoproteinemia Type I, Male, Middle Aged, Oligonucleotides, Platelet Count, RNA, Messenger, Thrombocytopenia, Triglycerides, Apolipoprotein C-III, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.